177Lu-PSMA was administered intravenously with 4–8 GBq per treatment cycle (varying 1–6 cycles in total). Any PSA decrease, >30% PSA decline and >50% PSA decline was reached in approximately 75%, 60% and 50%, respectively. Additionally, assessment with 68Ga-PSMA-HBED-CC PET/CT ...
Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomesdoi:10.1007/s40291-024-00699-wWhilst prostate cancer is the fourth most common cancer globally, effective therapies for patients with advanced disease are lacking. In...
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Targeted Radioligand Therapy for Treatment of Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for ...
EAST HANOVER, N.J., March 23, 2022 -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer ...
Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes 来自 Springer 喜欢 0 阅读量: 22 作者: H Nguyen,K Hird,J Cardaci,S Smith,NP Lenzo 展开 摘要: Whilst prostate cancer is the fourth most common cancer ...
Lutetium-177 Labeled Therapeutics: Lu-PSMA is Set to Redefine Prostate Cancer Treatment.doi:10.2174/187447100901151123124826Ambikalmajan M R PillaiF. KnappCurr RadiopharmCurrent radiopharmaceuticals
Treatment related toxicities occurred in 54.5% (12/22) of patients, including 22.7% with dry mouth, 22.7% with fatigue, and 13.6% with nausea.Conclusions:This dataset highlightsreal-world treatment patterns with177-Lu-PSMA, which is an active and well-tolerated therapy. Despite initial response,...
Lutetium-177-PSMA (Lu-PSMA), a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA), enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer (mCRPC). In a recent single-arm phase II trial and a subsequent expansion ...
Lutetium-177-prostate-specific membrane antigen (Lu-PSMA), a radiolabeled small molecule, binds with high affinity to prostate-specific membrane antigen, enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer (mCRPC). In a recent single-arm phase II trial and a ...
Lu-177 labeled therapeutics: 177Lu-PSMA is set to redefine prostate cancer treatment. Curr Radiopharm, 2016: 9(1): 6-7. PMID: 26655262Pillai AM, Knapp FF. Lutetium-177 labeled therapeutics: 177Lu- PSMA is set to redefine prostate cancer treatment. Curr Radiopharm. 2016;9:6-7....